BioSpace News Archive

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present at the 19th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2020 at 12:00 p.m. ET

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced the appointment of Myles Wolf , M.D., M.M.Sc., to its Board of Directors, effective April 6 . Dr. Wolf is a leading clinical nephrologist a

Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, today provided a status update on the company’s non-GCP Phase II trial evaluating the use of its proprietary neural stem cells, NSI-566, for the treatment of chronic ischemic stroke.

Pharmazam™, a world-class leading advanced genetic and personalized healthcare management company, has developed and deployed the most advanced, comprehensive personalized healthcare system, identifying potentially fatal medication combinations in the treatment of COVID-19 (https://pharmazam.com/covid-19).

Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA) today announced that the Centers for Medicare & Medicaid Services (CMS) established a new permanent J-code for Andexxa ® [coagulation factor Xa (recombinant), inactivated-zhzo] facilitating reimbursement in the hospital outpatient setting. The code, J7169 (Injection, c

Axcella today announced the issuance of U.S. Patent 10,596,136. This patent broadly covers the use of the company’s initial muscle product candidate, AXA

Moderna, Inc. announced that it will host its virtual Vaccines Day for analysts and investors at 8:00 a.m. ET on Tuesday, April 14.

Multi-faceted philanthropic package to support wide range of organizations and needs

Masimo (NASDAQ: MASI) announced today that St. Luke’s University Health Network (SLUHN) is one of the first institutions worldwide to use Masimo SafetyNet™ to monitor in-hospital patients, as the network seeks innovative solutions to care for the surge of patients infected by COVID-19.

InGeneron announces publication of favorable results using regenerative cells isolated from patients’ own body fat prepared with the Transpose® RT System in the Journal of Orthopaedic Surgery and Research.